Testing NT-I7 after CAR T-cell therapy for large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a drug called NT-I7 (efineptakin alfa) can help people with large B-cell lymphoma who have already received a CAR T-cell treatment like Yescarta or Breyanzi. It aims to boost your immune system's recovery and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have large B-cell lymphoma that has come back or not responded to previous treatment.
- You must have measurable disease on a PET/CT scan.
- You must be eligible to receive a standard CAR T-cell therapy (Yescarta or Breyanzi) as part of your treatment.
- You must be at least 18 years old.
- You must have adequate organ and bone marrow function, such as certain blood cell counts and kidney function.
- You cannot have active central nervous system involvement from lymphoma, uncontrolled heart disease, or certain autoimmune conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
This trial tests whether a drug called NT-I7 (a lab-made immune booster) can help people with multiple myeloma who have already received a CAR-T cell therapy called cilta-cel. It's for patients whose myeloma has come back or hasn't responded well to treatment.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
This trial is studying whether a new kind of cellular therapy, called anti-CD7 CAR-T, can help people with relapsed or refractory T-cell lymphoma/leukemia by targeting a specific protein (CD7) on their cancer cells. The treatment uses your own immune cells that are reprogrammed to find and destroy the malignant cells.
This trial tests a new treatment using specially engineered immune cells (CAR T cells) from a past stem cell donor to attack cancer cells in people with certain types of T-cell cancers that have returned after a stem cell transplant. The goal is to see if this treatment can lead to remission so a second stem cell transplant can be done.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.